Genelux Corporation Common Stock (GNLX)

Benchmark has reiterated a Speculative Buy rating and a $20.00 price target on Genelux Corp. due to the continued advancement of its cancer immunotherapy, Olvi-Vec, for aggressive solid tumors. The company expects Phase 3 data for ovarian cancer in late 2026 and has sufficient cash to fund operations into Q1 2027. Genelux also recently held its annual meeting, electing a new director and ratifying its auditor.

This article highlights bullish sentiments from analysts on three healthcare stocks: Auxly Cannabis Group (CBWTD), Genelux Corp. (GNLX), and NervGen Pharma (NGEN). Analysts from Haywood, H.C. Wainwright, and TD Cowen reiterated Buy ratings for these companies, providing specific price targets and detailing their upside potential based on current stock prices.

Genelux Corporation announced its financial results for the second quarter and first half of 2026. The company reported an increased net loss for both periods, with a net loss of USD 9.47 million for the second quarter and USD 18.4 million for the six months ended June 30, 2026. Basic and diluted loss per share also increased compared to the previous year.

Genelux (GNLX), a clinical-stage oncology biotech company, reported a widening net loss of $9.5 million for Q2 2026 and $18.4 million for the first half of 2026, primarily due to increased R&D expenses for its Phase 3 Olvi-Vec cancer trial. Despite a recent $18.5 million equity offering, the company's cash reserves of $18.7 million are projected to fund operations only into Q1 2027, leading to a "going concern" warning and a stated need for additional financing. The company continues to advance its lead product candidate, Olvi-Vec, and noted a publication of positive translational and clinical findings from its Phase 1b/2 VIRO-15 trial.

GENELUX Corp reported its financial results for the six months ended June 30, 2026, showing no revenue, a net loss of $(18.4M), and diluted EPS of $(0.41). The company's net loss worsened compared to the prior year, primarily due to increased clinical and regulatory spending for its lead oncolytic candidate, Olvi-Vec. GENELUX plans to continue expanding its clinical programs and funding operations into early 2027 through capital raised earlier in 2026.